|
1
|
Stewart B and Wild CP: World Health
OrganizationWorld cancer report 2014. IARC Press; Lyon: 2003
|
|
2
|
Yang JD and Roberts LR: Hepatocellular
carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 7:448–458.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang JH, Wang CC, Hung CH, Chen CL and Lu
SN: Survival comparison between surgical resection and
radiofrequency ablation for patients in BCLC very early/early stage
hepatocellular carcinoma. J Hepatol. 56:412–418. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thomas MB, O'Beirne JP, Furuse J, Chan AT,
Abou-Alfa G and Johnson P: Systemic therapy for hepatocellular
carcinoma: Cytotoxic chemotherapy, targeted therapy and
immunotherapy. Ann Surg Oncol. 15:1008–1014. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Uzma A and Tim M: Are there opportunities
for chemotherapy in the treatment of hepatocellular cancer? J
Hepatol. 56:686–695. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alcindor T and Beauger N: Oxaliplatin: A
review in the era of molecularly targeted therapy. Curr Oncol.
18:18–25. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Du H, Yang W, Chen L, Shi M, Seewoo V,
Wang J, Lin A, Liu Z and Qiu W: Role of autophagy in resistance to
oxaliplatin in hepatocellular carcinoma cells. Oncol Rep.
27:143–150. 2012.PubMed/NCBI
|
|
9
|
Alemany R, van Koppen CJ, Danneberg K, Ter
Braak M, Meyer Zu and Heringdorf D: Regulation and functional roles
of sphingosine kinases. Naunyn Schmiedebergs Arch Pharmacol.
374:413–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pyne NJ and Pyne S: Sphingosine
1-phosphate and cancer. Nat Rev Cancer. 10:489–503. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Heffernan-Stroud LA and Obeid LM:
Sphingosine kinase 1 in cancer. Adv Cancer Res. 117:201–235. 2012.
View Article : Google Scholar
|
|
12
|
Van Brocklyn JR, Jackson CA, Pearl DK,
Kotur MS, Snyder PJ and Prior TW: Sphingosine kinase-1 expression
correlates with poor survival of patients with glioblastoma
multiforme: Roles of sphingosine kinase isoforms in growth of
glioblastoma cell lines. J Neuropathol Exp Neurol. 64:695–705.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ruckhäberle E, Rody A, Engels K, Gaetje R,
von Minckwitz G, Schiffmann S, Grösch S, Geisslinger G, Holtrich U,
Karn T and Kaufmann M: Microarray analysis of altered sphingolipid
metabolism reveals prognostic significance of sphingosine kinase 1
in breast cancer. Breast Cancer Res Treat. 112:41–52. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sukocheva O, Wang L, Verrier E, Vadas MA
and Xia P: Restoring endocrine response in breast cancer cells by
inhibition of the sphingosine kinase-1 signaling pathway.
Endocrinology. 150:4484–4492. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rosa R, Marciano R, Malapelle U, Formisano
L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfè G, Del Vecchio
S, et al: Sphingosine kinase 1 overexpression contributes to
cetuximab resistance in human colorectal cancer models. Clin Cancer
Res. 19:138–147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guillermet-Guibert J, Davenne L,
Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C,
Delisle MB, Cuvillier O, Susini C and Bousquet C: Targeting the
sphingolipid metabolism to defeat pancreatic cancer cell resistance
to the chemotherapeutic gemcitabine drug. Mol Cancer Ther.
8:809–820. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maceyka M, Harikumar KB, Milstien S and
Spiegel S: Sphingosine-1-phosphate signaling and its role in
disease. Trends Cell Biol. 22:50–60. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kunkel GT, Maceyka M, Milstien S and
Spiegel S: Targeting the sphingosine-1-phosphate axis in cancer,
inflammation and beyond. Nat Rev Drug Discov. 12:688–702. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song L, Xiong H, Li J, Liao W, Wang L, Wu
J and Li M: Sphingosine kinase-1 enhances resistance to apoptosis
through activation of PI3K/Akt/NF-κB pathway in human non-small
cell lung cancer. Clin Cancer Res. 17:1839–1849. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ji F, Mao L, Liu Y, Cao X, Xie Y, Wang S
and Fei H: K6PC-5, a novel sphingosine kinase 1 (SphK1) activator,
alleviates dexamethasone-induced damages to osteoblasts through
activating SphK1-Akt signaling. Biochem Biophys Res Commun.
458:568–575. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ponnusamy S, Meyers-Needham M, Senkal CE,
Saddoughi SA, Sentelle D, Selvam SP, Salas A and Ogretmen B:
Sphingolipids and cancer: Ceramide and sphingosine-1-phosphate in
the regulation of cell death and drug resistance. Future Oncol.
6:1603–1624. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Patwardhan GA and Liu YY: Sphingolipids
and expression regulation of genes in cancer. Prog Lipid Res.
50:104–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rosen H, Gonzalez-Cabrera PJ, Sanna MG and
Brown S: Sphingosine 1-phosphate receptor signaling. Annu Rev
Biochem. 78:743–768. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ader I, Malavaud B and Cuvillier O: When
the sphingosine kinase 1/sphingosine 1-phosphate pathway meets
hypoxia signaling: New targets for cancer therapy. Cancer Res.
69:3723–3726. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Marfe G, Di Stefano C, Gambacurta A,
Ottone T, Martini V, Abruzzese E, Mologni L, Sinibaldi-Salimei P,
de Fabritis P, Gambacorti-Passerini C, et al: Sphingosine kinase 1
overexpression is regulated by signaling through PI3K, AKT2, and
mTOR in imatinib-resistant chronic myeloid leukemia cells. Exp
Hematol. 39:653–665.e6. 2011. View Article : Google Scholar : PubMed/NCBI
|
